Spots Global Cancer Trial Database for Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Official Title: A Phase II Study of Bevacizumab in Combination With Temozolomide in Patients With Advanced Neuroendocrine Tumors

Study ID: NCT00137774

Conditions

Neuroendocrine Tumors

Interventions

Bevacizumab

Temozolomide

Study Description

Brief Summary: The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

Detailed Description: Patients will receive temozolomide orally once daily for one week, followed by a one-week rest period. This one-week on/one week off schedule will continue for the duration of treatment unless significant side effects develop. Bevacizumab will be administered intravenously every other week. After eight weeks (two cycles), a CT scan will be performed to see how treatment affected tumor growth. Bactrim, an antibiotic, and acyclovir, an antiviral medicine, will be given in order to help prevent infection. Blood tests will be done every other week to evaluate any side effects. Once the study has been completed, a physical exam, vital signs, blood tests, and CT scan will be performed. Patients will remain on the study as long as they continue to receive benefit from the treatment and there are no serious side effects.